Management of depression in the presence of pain symptoms

Psychiatria Danubina

Volumn 22, Issue 1, 2010, Pages 4-13

  Mohr, Pavel ^a,b   Bitter, Istvań ^c   Sv̌estka, Jaromiŕ ^d   Seifritz, Erich ^e   Karamustafalioglu, Oguz ^f   Koponen, Hannu ^g   Sartorius, Norman ^h  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^e UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^f SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^g KUOPIO UNIVERSITY HOSPITAL   (Finland)

^h UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Analgesics; Anticonvulsants; Antidepressants; Depression; Pain; SNRI

Indexed keywords

ANALGESIC AGENT; CARBAMAZEPINE; CYCLOBENZAPRINE; DULOXETINE; GABAPENTIN; IMIPRAMINE; MIANSERIN; MILNACIPRAN; MIRTAZAPINE; NARCOTIC ANALGESIC AGENT; NEFAZODONE; NEUROTRANSMITTER; PLACEBO; PREGABALIN; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; CYCLOPROPANE DERIVATIVE; NORADRENALIN; SEROTONIN; THIOPHENE DERIVATIVE;

ANALGESIA; ARTHRALGIA; CLINICAL RESEARCH; COMORBIDITY; DISEASE SEVERITY; DRUG EFFICACY; FACE PAIN; FIBROMYALGIA; HUMAN; KNEE PAIN; MAJOR DEPRESSION; MIGRAINE AURA; NEUROPATHIC PAIN; NORADRENERGIC SYSTEM; PAIN; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PSYCHOTHERAPY; REVIEW; RISK FACTOR; SEROTONINERGIC SYSTEM; ALTERNATIVE MEDICINE; ARTICLE; BRAIN; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; BRAIN; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; COMORBIDITY; CYCLOHEXANOLS; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; FIBROMYALGIA; HUMANS; MIND-BODY RELATIONS (METAPHYSICS); NOREPINEPHRINE; PAIN; PSYCHOTHERAPY; SEROTONIN; THIOPHENES; TREATMENT OUTCOME;

EID: 77957683314     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. American Psychiatric Association practice guideline for the treatment of patients with major depressive disorder. Am J Psychiatry 2000;157(4 Suppl):1-45.
2. Argoff CE. The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach. Clin J Pain 2007; 23:15-22.
3. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-2984. (Pubitemid 39209537)
4. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15. (Pubitemid 41752960)
5. Arnold LM. Management of fibromyalgia and comorbid psychiatric disorders. J Clin Psychiatry 2008;69 Suppl 2:14-19.
6. Arnold LM, Meyers AL, Sunderajan P, Montano CB, Kass DO E, Trivedi M, Wohlreich MM. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder. Ann Clin Psychiatry 2008; 20:187-193.
7. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity. A literature review. Arch Gen Psychiatry 2003;163:2433-2445. (Pubitemid 37385786)
8. Bardin L, Gregoire S, Aliaga M, Malfetes N, Vitton O, Ladure P, Newman-Tancredi A, Depoortere R. Comparison of milnacipran, duloxetine and pregabalin in the formalin pain test and in a model of stress-induced ultrasonic vocalizations in rats. Neurosci Res 2010;66:135-140.
9. Beesdo K, Hartford J, Russell J, Spann M, Ball S, Wittchen HU. The short- and long-term effect of duloxetine on painful physical symptoms in patients with generalized anxiety disorder: results from three clinical trials. J Anxiety Disord 2009;23:1064-1071.
10. Begré S, Traber M, Gerber M, von Känel R. Change in pain severity with open label venlafaxine use in patients with a depressive symptomatology: an observational study in primary care. Eur Psychiatry 2008;23:178-186.
11. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005;39:43-53. (Pubitemid 39422285)
12. Brecht S, Courtecuisse C, Debieuvre C, Croenlein J, Desaiah D, Raskin J, Petit C, Demyttenaere K. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. J Clin Psychiatry. 2007 Nov;68:1707-1716. (Pubitemid 350247500)
13. Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004 Dec;107:44-8 (Pubitemid 39556678)
14. Chappell AS, Bradley LA, Wiltse C, Detke MJ, D'Souza DN, Spaeth M. A six-month doubleblind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med 2008;1:91-102.
15. Chappell AS, Ossanna MJ, Liu-Seifert H, Iyengar S, Skljarevski V, Li LC, Bennett RM, Collins H. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain 2009;146:253-260.
16. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30:1988-2004.
17. Clauw DJ. Pharmacotherapy for patients with fibromyalgia. J Clin Psychiatry 2008;69 (Suppl 2): 25-9.
18. Crofford LJ. Pain management in fibromyalgia. Curr Opin Rheumatol 2008;20:246-250. (Pubitemid 351483311)
19. Doan BD, Wadden NP. Relationships between depressive symptoms and descriptions of chronic pain. Pain 1989;36:75-84. (Pubitemid 19024968)
20. Ehnvall A, Mitchell PB, Hadzi-Pavlovic D, Malhi GS, Parker G. Pain during depression and relationship to rejection sensitivity. Acta Psychiatr Scand 2009;119:375-382.
21. Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 2004;65:521-530.
22. Forssell H, Tasmuth T, Tenovuo O, Hampf G, Kalso E. Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. J Orofac Pain 2004; 18:131-137. (Pubitemid 38623995)
23. Freynhagen R, Muth-Selbach U, Lipfert P, Stevens MF, Zacharowski K, Tölle TR, von Giesen HJ. The effect of mirtazapine in patients with chronic pain and concomitant depression. Curr Med Res Opin 2006; 22:257-264. (Pubitemid 44296749)
24. Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, Williams DA, Mease PJ, McLean SA, Clauw DJ. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005; 32:1975-1985. (Pubitemid 41429029)
25. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116:109-118. (Pubitemid 40828506)
26. Gruener DM. New Strategies for Managing Acute Pain Episodes in Patients With Chronic Pain. Medscape Neurology & Neurosurgery 2004; 6(2).
27. Häuser W, Bernardy K, Uçeyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA 2009; 301:198-209.
28. Howland RH, Wilson MG, Kornstein SG, Clayton AH, Trivedi MH, Wohlreich MM, Fava M. Factors Predicting Reduced Antidepressant Response: Experience with the SNRI Duloxetine in Patients with Major Depression. Ann Clin Psychiatry. 2008; 20:209-218.
29. Jakovljević M: Transdisciplinary Holistic Integrative Psychiatry - A Wishfull Thinking or Reality? Psychiatria Danubina 2008; 20:341-8.
30. Kadiroglu AK, Sit D, Kayabasi H, Kemal Tuzcu A, Tasdemir N, Yilmaz ME. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. J Diabetes Complications 2008; 22:241-245. (Pubitemid 351885487)
31. Katon W, Lin EHB, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry 2007; 29:147-155.
32. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008;5:e45.
33. Krebs EE, Gaynes BN, Gartlehner G, Hansen RA, Thieda P, Morgan LC, DeVeaugh-Geiss A, Lohr KN. Treating the physical symptoms of depression with second-generation antidepressants: a systematic review and metaanalysis. Psychosomatics 2008; 49:191-198. (Pubitemid 351668719)
34. Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry 2009; 31:206-219.
35. Leo RJ, Pristach CA, Streltzer J. Incorporating pain management training into the psychiatry residency curriculum. Acad Psychiatry 2003;27:1-11. (Pubitemid 36249762)
36. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev 2009;(4):CD007115.
37. Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, Palmer RH. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009; 36:398-409.
38. Molton IR, Graham C, Stoelb BL, Jensen MP. Current psychological approaches to the management of chronic pain. Curr Opin Anaesthesiol 2007; 20:485-489. (Pubitemid 47415139)
39. Nemeroff CB. Recent advances in the neurobiology of depression. Psychopharmacol Bull 2002;36 (suppl. 2):6-23.
40. Nemeroff CB, Vale WW. The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry 2005; 66(Suppl. 7):5-13. (Pubitemid 41345489)
41. Nunes EV, Sullivan MA, Levin FR. Treatment of depression in patients with opiate dependence. Biol Psychiatry 2004; 56:793-802. (Pubitemid 39539838)
42. Nyhuis PW, Gastpar M, Scherbaum N. Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy. J Clin Psychopharmacol 2008; 28:593-595.
43. Owen RT. Pregabalin: its efficacy, safety and tolerability profile in fibromyalgia syndrome. Drugs Today 2007; 43:857-863. (Pubitemid 351160481)
44. Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005; 45:144-152. (Pubitemid 40315784)
45. Passier A, van Puijenbroek E. Mirtazapine-induced arthralgia. Br J Clin Pharmacol 2005;60:570-572. (Pubitemid 41532459)
46. Perahia DG, Quail D, Desaiah D, Montejo AL, Schatzberg AF. Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: Effects on painful physical symptoms of depression. J Psychiatr Res 2009;43:512-518.
47. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-281. (Pubitemid 20187930)
48. Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, Wernicke JF. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-356. (Pubitemid 41727332)
49. Raskin J, Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ, Rotz BT, Mohs RC. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007;164:900-909. (Pubitemid 46972905)
50. Reeves RR, Cox SK. Similar effects of tramadol and venlafaxine in major depressive disorder. South Med J 2008;101:193-195.
51. Réthelyi JM, Berghammer R, Kopp MS. Comorbidity of pain-associated disability and depressive symptoms in connection with sociodemographic variables: results from a cross-sectional epidemiological survey in Hungary. Pain 2001; 93:115-121. (Pubitemid 32568396)
52. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004;110:697-706. (Pubitemid 39036802)
53. Rush AJ. The varied clinical presentations of major depressive disorder. J Clin Psychiatry 2007; 68(suppl. 8):4-10. (Pubitemid 47184565)
54. Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, Walker DJ, Chappell AS, Arnold LM. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:432-444.
55. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007; (3):CD005454.
56. Salerno SM, Browning R, Jackson JL. The effect of antidepressant treatment on chronic back pain. Arch Intern Med 2002;162:19-24. (Pubitemid 34073395)
57. Schreiber S, Bleich A, Pick CG. Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects--a possible opioid involvement in severe depression? J Mol Neurosci 2002;18:143-149. (Pubitemid 34256401)
58. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003;60:1284-1289. (Pubitemid 36460983)
59. Skljarevski V, Ossanna M, Liu-Seifert H, Zhang Q, Chappell A, Iyengar S, Detke M, Backonja M. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol 2009; 16:1041-1048.
60. Spielmans GI. Duloxetine does not relieve painful physical symptoms in depression: a meta-analysis. Psychother Psychosom 2008;77:12-16. (Pubitemid 350261943)
61. Steptoe A (Ed). Depression and physical illness. Cambridge University Press, Cambridge UK 2007, 421 pp.
62. Straube S, Derry S, Moore RA, McQuay HJ. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford) 2010, in press.
63. Tasmuth T, Härtel B, Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 2002;6:17-24.
64. Van Puymbroeck CM, Zautra AJ, Harakas PP. Chronic pain and depression: twin burdens of adaptation. In: Steptoe A (Ed). Depression and physical illness. Cambridge University Press, Cambridge UK 2007, pp. 145-164.
65. Volpe FM. An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache. J Clin Psychiatry 2008;69:1449-1454.
66. Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P, Iyengar S, Raskin J. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67:1411-1420. (Pubitemid 44632065)
67. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev 2005; (3):CD001133.
68. Wise TN, Fishbain DA, Holder-Perkins V. Painful physical symptoms in depression: a clinical challenge. Pain Med 2007;8 (suppl.2): S75-S82. (Pubitemid 47288513)
69. Wise TN, Meyers AL, Desaiah D, Mallinckrodt CH, Robinson MJ, Kajdasz DK. The significance of treating somatic symptoms on functional outcome improvement in patients with major depressive disorder: a post hoc analysis of 2 trials. Prim Care Companion J Clin Psychiatry 2008;10:270-275.
70. Woolf CJ; American College of Physicians; American Physiological Society. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004;140:441-451.
71. Yucel A, Ozyalcin S, Koknel Talu G, Kiziltan E, Yucel B, Andersen OK, Arendt-Nielsen L, Disci R. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. Eur J Pain 2005;9:407-416. (Pubitemid 40836035)
72. Zissis NP, Harmoussi S, Vlaikidis N, Mitsikostas D, Thomaidis T, Georgiadis G, Karageorgiou K. A randomized, double-blind, placebo-controlled study of venlafaxine XR in out-patients with tension-type headache. Cephalalgia 2007; 27:315-324. (Pubitemid 46434967)